Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria: * Histologically or cytologically documented malignancy (solid tumor or lymphoma) * Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2 * Predicted life expectancy of at least 3 months * Adequate hematopoietic and hepatic function, and normal renal function * Fasting glucose \<7mmol/L at baseline * Left ventricular ejection fracture (LVEF) by Multiple gated acquisition scan (MUGA)≥ 60% * Practice effective contraceptive measures throughout study * Verbal and written informed consent * Prior therapy: * Chemotherapy, minimum of 3 weeks and recovered from any treatment-related toxicities (except for alopecia, and grade 1 neurotoxicity) prior to registration * Hormonal, discontinued prior to registration * Radiation, minimum of 21 days and recovered from toxic effects prior to registration * Surgery, provided wound healing has occurred Exclusion Criteria: * History of significant cardiac disease unless well controlled * Discontinuation from prior therapy due to cardiac toxicity * Active or uncontrolled infections * Serious illness or medical condition that could interfere with study participation * History of any psychiatric condition that might impair understanding or compliance * Documented history of diabetes mellitus * Pregnant or breastfeeding females * Unstable symptomatic brain metastases, that require steroid or that have required radiation in the last 28 days * Chronic systemic steroid use for cancer related condition * History of allergic reactions * Patients with cataract who are expected to undergo surgery within 6 months of registration * Use of drugs causing QT interval prolongation within 14 days prior to dosing * Patients with clinically significant electrolyte imbalances